The HCM Puzzle: Why Drugs That Remodel the Heart Don’t Always Translate to Relief
Recent trials exploring myosin inhibitors – drugs designed to modulate heart muscle contraction – have yielded a fascinating and somewhat perplexing, result in hypertrophic cardiomyopathy (HCM). While these medications demonstrably change the heart’s structure in patients with non-obstructive HCM (nHCM), they haven’t yet consistently translated into noticeable improvements in how patients feel or perform during exercise. This disconnect is prompting a re-evaluation of treatment strategies and a deeper dive into the complexities of this condition.
Biologic Improvements, Clinical Stalemate: The ODYSSEY-HCM Findings
The ODYSSEY-HCM trial, a phase 3 study evaluating mavacamten in symptomatic nHCM, revealed a striking biological response. Researchers observed a significant 58% reduction in NT-proBNP levels and a 51% reduction in high-sensitivity cardiac troponin I (hs-cTnI) – biomarkers indicating heart stress – in patients taking mavacamten compared to placebo. Echocardiographic parameters also showed improvements, including reductions in wall thickness and left atrial size. However, these changes didn’t translate into statistically significant improvements in peak oxygen consumption (VO2) or the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS), the trial’s primary endpoints.
Why the Disconnect? nHCM is Not Just Obstructed HCM Without a Gradient
Experts are increasingly emphasizing that nHCM isn’t simply oHCM without a left ventricular outflow tract (LVOT) gradient. The underlying mechanisms driving symptoms differ. While reducing hypercontractility with myosin inhibitors is effective in oHCM by alleviating the obstruction, nHCM symptoms stem from a more complex interplay of factors including diastolic dysfunction, impaired LV reserve, microvascular ischemia, and abnormal energetics. Addressing hypercontractility alone may not be enough.
The Role of Disease Duration and Structural Remodeling
The ODYSSEY-HCM trial included patients with a mean disease duration of approximately 10 years. It’s possible that long-standing nHCM leads to fixed structural remodeling and comorbidities that are less responsive to short-term interventions like mavacamten. Reverse remodeling, the process of the heart returning to a healthier state, may require years, not months, to impact exercise capacity in these patients. Some patients may even have “burned-out” oHCM, with fibrosis masking previous obstruction.
Safety Considerations: The LVEF Ceiling
A significant proportion of patients (21.5%) receiving mavacamten in the ODYSSEY-HCM trial experienced a decline in left ventricular ejection fraction (LVEF) to below 50%, necessitating dose interruptions. This highlights a “safety ceiling” and suggests that sustained sarcomere modulation, crucial for improving diastolic filling, may be hindered by the need to avoid significant LVEF reduction.
Aficamten and the Ongoing Search for Solutions
Despite the neutral clinical results with mavacamten in nHCM, research continues. The REDWOOD-HCM trial showed promising results with aficamten, another myosin inhibitor, demonstrating improvements in NYHA class, NT-proBNP levels, and KCCQ-CSS. This has spurred the ACACIA-HCM trial, currently underway, to further evaluate aficamten’s efficacy and safety in symptomatic nHCM.
A Tale of Two HCMs: Contrasting Responses to Myosin Inhibition
The success of myosin inhibitors in oHCM is undeniable. Trials like EXPLORER-HCM and SEQUOIA-HCM have demonstrated significant improvements in VO2, KCCQ-CSS, LVOT gradients, and NYHA class. This stark contrast underscores the fundamental differences between nHCM and oHCM, and the need for tailored treatment approaches. (Spot Table 1 for a detailed comparison).
What’s Next? A Multifaceted Approach to nHCM
Currently, myosin inhibitors should be reserved for use within the context of randomized controlled trials for nHCM. Guideline-directed medical therapy remains focused on beta-blockers (BBs) and non-dihydropyridine calcium channel blockers (NDHP-CCBs), alongside management of atrial fibrillation, comorbidities, and cautious diuretic use. However, the future of nHCM treatment likely lies in a more multifaceted approach.
Exploring Combination Therapies
Researchers are investigating combination therapies that target multiple aspects of the disease, including microvascular dysfunction, energetics, and fibrosis, alongside sarcomere inhibition. Earlier therapeutic intervention, before significant structural remodeling occurs, may also prove beneficial.
The Need for Better Phenotyping
Improved patient phenotyping – a more precise characterization of the disease – is crucial. Identifying specific subgroups of nHCM patients who are most likely to respond to particular therapies will be key to optimizing treatment outcomes.
FAQ: Myosin Inhibitors and HCM
- What is myosin inhibition? It’s a therapeutic approach that reduces the force of heart muscle contraction by targeting the interaction between myosin and actin proteins.
- Why didn’t mavacamten improve symptoms in ODYSSEY-HCM? While mavacamten changed the heart’s structure, it didn’t significantly improve how patients felt or performed during exercise, likely because nHCM symptoms are driven by multiple factors beyond hypercontractility.
- Is aficamten different from mavacamten? Both are myosin inhibitors, but they may have different effects and safety profiles. Aficamten has shown more promising early results in nHCM.
- What is the current standard of care for nHCM? Beta-blockers and non-dihydropyridine calcium channel blockers remain the cornerstone of treatment, along with management of comorbidities.
Pro Tip: If you’ve been diagnosed with HCM, it’s crucial to function closely with a cardiologist specializing in this condition to develop a personalized treatment plan.
Stay informed about the latest advancements in HCM research and treatment. Explore additional resources from the American Heart Association and the Hypertrophic Cardiomyopathy Association.
